Lemon_tm
Capricor Therapeutics (CAPR) is down ~67% in Monday morning trading after the US released a briefing document ahead of a July 29 advisory committee meeting that called into question the efficacy and safety profile of its Duchenne muscular dystrophy candidate deramiocel.
